JP2009545619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545619A5 JP2009545619A5 JP2009523049A JP2009523049A JP2009545619A5 JP 2009545619 A5 JP2009545619 A5 JP 2009545619A5 JP 2009523049 A JP2009523049 A JP 2009523049A JP 2009523049 A JP2009523049 A JP 2009523049A JP 2009545619 A5 JP2009545619 A5 JP 2009545619A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutical formulation
- cisplatin
- administration
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 68
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 55
- 229960004316 cisplatin Drugs 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 50
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229940127089 cytotoxic agent Drugs 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 14
- 201000001119 neuropathy Diseases 0.000 claims description 13
- 230000007823 neuropathy Effects 0.000 claims description 13
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 13
- 230000000977 initiatory effect Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 150000003839 salts Chemical group 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 4
- 229960001278 teniposide Drugs 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical group C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- JMPOIZCOJJMTHI-UHFFFAOYSA-N leteprinim Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 JMPOIZCOJJMTHI-UHFFFAOYSA-N 0.000 claims description 3
- 229950011566 leteprinim Drugs 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 229960000473 altretamine Drugs 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960005314 suramin Drugs 0.000 claims description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004355 vindesine Drugs 0.000 claims description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 28
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82108206P | 2006-08-01 | 2006-08-01 | |
| PCT/US2007/075008 WO2008017000A2 (en) | 2006-08-01 | 2007-08-01 | Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545619A JP2009545619A (ja) | 2009-12-24 |
| JP2009545619A5 true JP2009545619A5 (enExample) | 2011-09-22 |
Family
ID=38744846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523049A Withdrawn JP2009545619A (ja) | 2006-08-01 | 2007-08-01 | 化学療法誘発神経障害の治療に寄与するための方法および医薬製剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2046335A2 (enExample) |
| JP (1) | JP2009545619A (enExample) |
| KR (1) | KR20090047501A (enExample) |
| CN (1) | CN101657199A (enExample) |
| BR (1) | BRPI0715504A2 (enExample) |
| CA (1) | CA2659477A1 (enExample) |
| IL (1) | IL196824A0 (enExample) |
| MX (1) | MX2009001116A (enExample) |
| NO (1) | NO20090279L (enExample) |
| RU (1) | RU2009107123A (enExample) |
| WO (1) | WO2008017000A2 (enExample) |
| ZA (1) | ZA200900728B (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002004448A2 (en) * | 2000-07-07 | 2002-01-17 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy and related conditions |
-
2007
- 2007-08-01 BR BRPI0715504-2A patent/BRPI0715504A2/pt not_active IP Right Cessation
- 2007-08-01 CA CA002659477A patent/CA2659477A1/en not_active Abandoned
- 2007-08-01 MX MX2009001116A patent/MX2009001116A/es not_active Application Discontinuation
- 2007-08-01 KR KR1020097004261A patent/KR20090047501A/ko not_active Withdrawn
- 2007-08-01 EP EP07840646A patent/EP2046335A2/en not_active Withdrawn
- 2007-08-01 JP JP2009523049A patent/JP2009545619A/ja not_active Withdrawn
- 2007-08-01 CN CN200780028717A patent/CN101657199A/zh active Pending
- 2007-08-01 WO PCT/US2007/075008 patent/WO2008017000A2/en not_active Ceased
- 2007-08-01 RU RU2009107123/15A patent/RU2009107123A/ru not_active Application Discontinuation
-
2009
- 2009-01-19 NO NO20090279A patent/NO20090279L/no not_active Application Discontinuation
- 2009-01-30 ZA ZA200900728A patent/ZA200900728B/xx unknown
- 2009-02-01 IL IL196824A patent/IL196824A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2013503174A5 (enExample) | ||
| JP2019521180A5 (enExample) | ||
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP2007518805A5 (enExample) | ||
| JP2012506448A (ja) | 低酸素活性化型プロドラッグを用いるがんの処置 | |
| JP2010523696A5 (enExample) | ||
| JP2019533684A5 (enExample) | ||
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| JP2016515628A5 (enExample) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| EP2359860B1 (en) | Polymer micelle composition for treatment of resistant cancer cells | |
| JP2017513809A5 (enExample) | ||
| JP2014525449A5 (enExample) | ||
| JP7193591B2 (ja) | 化学療法の改善 | |
| CN1429114A (zh) | 联合化学疗法 | |
| JP2017516802A (ja) | がんの治療におけるエリブリンの使用 | |
| CA2836385A1 (en) | Method for treatment of advanced solid tumors | |
| JP2019524713A5 (enExample) | ||
| KR20210005714A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| CN112245419A (zh) | 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法 | |
| TW200940062A (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| KR20210008527A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법 | |
| US20170112807A1 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin c |